Introduction
============

The mechanism that determines the difference between asymptomatic sensitisation and clinical reactivity to food is as yet unknown. The aim of this study was to determine the effect of loss-of-function variants in the *filaggrin* gene on clinical reactivity, sensitisation and severity of food allergy.

Methods
=======

Cases were defined as children with a positive DBPCFC to at least one food. Controls were defined as children with negative DBPCFCs to all foods tested. Specific IgE was measured by CAP-FEIA and a severity score was based on the symptoms during the DBPCFC. Four gene variants were genotyped: *R501XZ*, *S3247X*, *2282Del4* and *R2447X.*

Results
=======

We included 173 children and of these, 18 children were excluded due to Mendelian errors, low call rate, diagnostic indistinctness or non-western ethnicity.

The odds ratio for having loss-of-function variants of the *filaggrin* gene and being clinically reactive was 4.9, which corresponds to a relative risk of 1.5.

A history of eczema or specific IgE values did not change the beta coefficient of the effect of the *filaggrin* loss-of-function gene variants ≥10%, and both variables were therefore not considered to be confounders in this association.

A predictive model for clinical reactivity which included the presence of loss-of-function variants of the *filaggrin* gene had high specificity (98.1%) and positive predictive value (96.6%).

No associations were found between loss-of-function variants of the *filaggrin* gene and either sensitisation or the severity of food allergy.

Conclusion and discussion
=========================

Of children suspected of being food allergic, those with loss-of-function variants of the *filaggrin* gene are 1.5 times more likely to be clinically reactive to a food than those carrying wild type alleles. This result is not confounded by eczema or specific IgE levels. These gene variants may help predict clinical reactivity in high risk children.
